Seminars in Cancer Biology

Article	Citations
Editorial Board	398
Editorial Board	344
Critical DNA damaging pathways in tumorigenesis	271
Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes	249
Small secretory proteins of immune cells can modulate gynecological cancers	224
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	223
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	201
Emerging applications of bacteria as antitumor agents	191
Advances in biology and novel treatments of SCLC	185
Deregulated transcription factors in the emerging cancer hallmarks	183
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	178
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	173
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	172
Breast cancer metastasis to bone: From epithelial to mesenchymal transition to breast osteoblast-like cells	171
Multifaceted role of chemokines in solid tumors: From biology to therapy	166
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	166
Editorial Board	166
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	160
Editorial Board	156
Origins and molecular effects of hypoxia in cancer	152
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	150
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	149
Genome chaos: Creating new genomic information essential for cancer macroevolution	144
Gut microbes in gastrointestinal cancers	136
Innovative trial design in precision oncology	133

The IL-1 family in tumorigenesis and antitumor immunity	132
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	131
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	130
Genomic profiling of sporadic liver metastatic colorectal cancer	129
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	123
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	121
Immune cellular components and signaling pathways in the tumor microenvironment	118
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	113
PIWI-interacting RNAs in human cancer	112
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	112
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	111
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	110
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	107
Anticancer properties of chimeric HDAC and kinase inhibitors	106
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	106
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	106
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	105
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	105
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	105
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	103
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	102
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	101
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	100
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	99
Anticancer natural products targeting immune checkpoint protein network	96
Editorial Board	95
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	94
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	94
Integrative microphysiological tissue systems of cancer metastasis to the liver	94
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	93
The intricacies of NRF2 regulation in cancer	93
Reprogramming of glycolysis by chemical carcinogens during tumor development	93
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	93
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	92
How far have we explored fungi to fight cancer?	92
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	92
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	88
Editorial Board	88
Editorial Board	87
Prostate cancer liver metastasis: Dormancy and resistance to therapy	87
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	86
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	85
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	85
The foundational framework of tumors: Gametogenesis, p53, and cancer	85
The role of RNA processing and regulation in metastatic dormancy	85
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	84
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	84
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	83
Analytical demands to use whole-genome sequencing in precision oncology	82
The role of tumor microenvironment and exosomes in dormancy and relapse	80

Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	80
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	80
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	79
MITOCHONDRIAL CHOLESTEROL AND CANCER	78
Microbiota and lung cancer	77
Clinical utility of whole-genome sequencing in precision oncology	77
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	76
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	74
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	73
Advancements in small cell lung cancer	72
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	72
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	71
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	70
Holistic immunomodulation for small cell lung cancer	68
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	68
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	68
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	66
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	64
CRISPR/Cas mediated epigenome editing for cancer therapy	64
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	64
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	63
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	63
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	62
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	62
Paradoxes of cancer: Survival at the brink	62
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art	62
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	61
Anticancer activity of lactic acid bacteria	61
Targeting p53 for the treatment of cancer	61
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	61
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	61
Thematic issue ‘tumor glycolysis’	60
Excess body weight: Novel insights into its roles in obesity comorbidities	60
Gut microbiome: A possible common therapeutic target for treatment of atherosclerosis and cancer	60
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	60
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	60
Editorial Board	59
Editorial Board	58
Transfer RNA-derived small RNA: A rising star in oncology	58
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	58
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	58
Human cell polyploidization: The good and the evil	58
Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model	56
Deregulated transcription factors and poor clinical outcomes in cancer patients	55
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	55
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	55
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	55
The central role of mitochondria in the relationship between dietary lipids and cancer progression	55
TGF-β, EMT, and resistance to anti-cancer treatment	54
Diet and cancer risk reduction: The role of diet-microbiota interactions and microbial metabolites	54
SR-BI as a target of natural products and its significance in cancer	54
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	54
Gut microbiota and immunosenescence in cancer	53
The impact of VEGF on cancer metastasis and systemic disease	53
Editorial Board	53
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	53
cGAS/STING signalling pathway in senescence and oncogenesis	52
Precision diagnostics in lymphomas – Recent developments and future directions	52
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	52
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	52
Possible connection between diet and microRNA in cancer scenario	52
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	52
The intricate nature of senescence in development and cell plasticity	51
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	51
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	51
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	51
Role of endolysosome function in iron metabolism and brain carcinogenesis	51
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	50
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	50
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	50
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	50
Transcriptional factors targeting in cancer stem cells for tumor modulation	50
Alternative splicing in EMT and TGF-β signaling during cancer progression	50
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	50
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	49
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	49
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	49
Editorial Board	49
Editorial Board	49
Artificial intelligence aids in development of nanomedicines for cancer management	49

Editorial Board	49
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	48
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	48
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	48
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	48
Can medical imaging identify the histopathological growth patterns of liver metastases?	48
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	47
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	47
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	47
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	47
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	47
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	47
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	47
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	47
Small cell lung cancer: Novel treatments beyond immunotherapy	47
Precision medicine in pediatric solid cancers	46
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	46
Nanoparticles: Attractive tools to treat colorectal cancer	46
The altered lipidome of hepatocellular carcinoma	46
Predicting liver metastases growth patterns: Current status and future possibilities	46
Hedgehog signaling mechanism and role in cancer	45
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	45
Predictive biomarkers for response to immune checkpoint inhibition	45
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	44
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	44
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	44
Sphingolipids in embryonic development, cell cycle regulation, and stemness – Implications for polyploidy in tumors	43
Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities	43
Liver prometastatic reaction: Stimulating factors and responsive cancer phenotypes	43
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease	43
Ethical challenges of precision cancer medicine	43
Understanding RNA-binding proteins	43
The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions	43